Apr 25, 2025
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
Jul 15, 2024
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Dec 18, 2020
Swissmedic approves Buvidal for the treatment of opioid dependence
Jun 01, 2020
Camurus Announces Submission of Request for Final Approval of Brixadi(TM) for the Treatment of Opioid Use Disorder in the US
Apr 02, 2020
Camurus Announces Strong First Quarter Demand for Buvidal®
Nov 25, 2019
Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Treatment of Opioid Dependence
Nov 07, 2019
Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi(TM) From the US market
Jul 23, 2019
Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi(TM)
Jun 20, 2019
Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Jun 04, 2019
Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal®
May 09, 2019
Camurus Interim Report January-March 2019
Apr 09, 2019
Braeburn Initiates Court Proceedings to Overturn Exclusivity and Seeks Immediate Market Approval of Brixadi(TM) in the US
Nov 28, 2018
Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependence
Nov 22, 2018
Camurus Receives EU Approval for Weekly and Monthly Buvidal® (CAM2038) for Opioid Dependence
Oct 10, 2018
Camurus to Present at Jefferies 2018 London Healthcare Conference
Sep 21, 2018
CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence
Sep 18, 2018
Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain
Jul 16, 2018
Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
Sep 29, 2017
Camurus Announces European Medicines Agency Validation of CAM2038 Marketing Authorization Application for Treatment of Opioid Dependence
Sep 18, 2017
Camurus Announces That FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder